Garcinia cambogia extract

Garcinia cambogia extract 是一种具有口服活性的抗肥胖剂,可上调 aP2、SREBP1c、PPARγ2、C/EBPα 基因表达,降低体重增长幅度、内脏脂肪堆积量以及血液、肝脏中的脂质和血浆胰岛素与瘦素水平,并改善高脂饮食诱导的肥胖。
产品编号: MS-B92315 CAS No.: 90045-23-1
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
3-5 天
100mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
询价
50g
询价
询价

产品描述

Garcinia cambogia extract 是一种具有口服活性的抗肥胖剂,可上调 aP2、SREBP1c、PPARγ2、C/EBPα 基因表达,降低体重增长幅度、内脏脂肪堆积量以及血液、肝脏中的脂质和血浆胰岛素与瘦素水平,并改善高脂饮食诱导的肥胖。

生物实验数据

生物活性 Garcinia cambogia extract is an orally active anti-obesity agent that upregulates the gene expression of aP2, SREBP1c, PPARγ2, and C/EBPα, reduces body weight gain, visceral fat accumulation, lipids in blood and liver, and plasma insulin and leptin levels, and ameliorates high-fat diet-induced obesity.
IC50 & Target

PPARγ2

 

aP2

 

体内研究
(In Vivo)

Garcinia cambogia extract (通过饲料口服,每日自由采食,12 周,10000 ppm) 可通过降低体重增长、内脏脂肪堆积和血脂异常,以及恢复内脏脂肪组织中脂肪生成相关基因的表达,减轻雄性 C57BL/6J 小鼠中 HFD 诱导的肥胖。

Animal Model: C57BL/6J (7-week-old male, high-fat diet-induced obesity model)
Dosage: 10 g/kg diet (extract contained 60% hydroxycitric acid)
Administration: dietary incorporation; ad libitum daily; 12 weeks
Result: Reduced final body weight by 22% and 12-week body weight gain by 46% compared to HFD-fed controls.
Reduced food intake and food efficiency ratio significantly compared to HFD-fed controls.
Reduced total visceral fat depot weight by 39% compared to HFD-fed controls; epididymal, perirenal, retroperitoneal, and mesenteric fat pad weights were reduced by 37%, 48%, 36%, and 42% respectively.
Reduced mean epididymal adipocyte surface area by 34% compared to HFD-fed controls.
Reduced plasma total cholesterol by 24% and plasma triglycerides by 25% compared to HFD-fed controls.
Reduced liver weight by 18%, hepatic triglyceride levels by 14%, and hepatic cholesterol levels by 15% compared to HFD-fed controls.
Reduced plasma insulin levels by 43% and plasma leptin levels by 52% compared to HFD-fed controls.
Increased aP2 mRNA by 120%, SREBP1c mRNA by 12%, C/EBPα mRNA by 174%, and PPARγ2 mRNA by 70% in epididymal fat tissue compared to HFD-fed controls.
Decreased TNFα mRNA by 20% in epididymal fat tissue compared to HFD-fed controls.
性状 固体
颜色 Off-white to light yellow

化学信息

CAS No. 90045-23-1

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础